OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Joseph on Selecting Frontline Therapy in mRCC

August 3rd 2019

Richard W. Joseph, MD, internist and oncologist, Mayo Clinic, discusses the process of selecting frontline therapy in metastatic renal cell carcinoma (mRCC).

Dr. Siddiqi on the CLL14 Trial Results in CLL

August 3rd 2019

Tanya Siddiqi, MD, a hematologist/oncologist at City of Hope, discusses the CLL14 trial, which tested venetoclax (Venclexta) plus obinutuzumab (Gazyva) versus obinutuzumab plus chlorambucil in patients with previously untreated chronic lymphocytic leukemia and coexisting conditions.

Dr. Thiel on Overall Survival Data From the CARMENA Trial in mRCC

August 2nd 2019

David D. Thiel, MD, chair, Department of Urology, Mayo Clinic, discusses the phase III randomized CARMENA trial, which examined cytoreductive nephrectomy plus sunitinib versus sunitinib alone in patients with metastatic renal cell carcinoma.

Dr. Shaw on Sequencing Strategies in ALK-Positive NSCLC

August 2nd 2019

Alice T. Shaw, MD, PhD, associate professor of medicine at Harvard Medical School, director of Thoracic Oncology and Paula O’Keefe Endowed Chair in Thoracic Oncology at Massachusetts General Hospital, discusses sequencing strategies in ALK-positive non–small cell lung cancer (NSCLC).

Dr. Gasparetto on Key Trials in Relapsed/Refractory Multiple Myeloma

August 2nd 2019

Cristina Gasparetto, MD, an associate professor of medicine, Duke University Medical Center, and director, Multiple Myeloma Program at Duke Cancer Institute, discusses key trials in relapsed/refractory multiple myeloma.

Dr. Kasi on the Use of Liquid Biopsies in CRC

August 2nd 2019

Pashtoon M. Kasi, MBBS, MD, MS, hematologist, internist, oncologist, Mayo Clinic, discusses the comparison of circulating tumor DNA tests, tissue, and liquid biopsies, in a study of patients with colorectal cancer.

Dr. Singh on the Prevalence of Genomic Testing in Urothelial Cancer

August 1st 2019

Parminder Singh, MD, hematologist/oncologist, Mayo Clinic, discusses the prevalence of genomic testing in urothelial cancer.

Dr. Saba on Treatment Deintensification in HPV-Related Oropharyngeal Squamous Cell Carcinoma

August 1st 2019

Nabil F. Saba, MD, FACP, director, Head and Neck Medical Oncology Program, Winship Cancer Institute of Emory University, professor, Department of Hematology and Medical Oncology, Department of Otolaryngology, Emory University School of Medicine, discusses treatment deintensification for patients with HPV-related oropharyngeal squamous cell carcinoma.

Dr. Meisel on Optimizing Genomic Assays in Early-Stage HR-Positive, HER2-Negative Breast Cancer

August 1st 2019

Jane L. Meisel, MD, an assistant professor, Department of Hematology and Medical Oncology and Department of Gynecology & Obstetrics, Winship Cancer Institute, Emory University School of Medicine, discusses optimizing genomic assays in early-stage hormone receptor (HR)–positive, HER2-negative breast cancer.

Dr. Pullarkat on Assessing for MRD in ALL

August 1st 2019

Vinod A. Pullarkat, MD, clinical professor of Hematology & Hematopoietic Cell Transplantation, and hematologist/oncologist, discusses the importance of assessing for minimal residual disease in acute lymphoblastic leukemia.

Dr. Stadler on Active Surveillance in Prostate Cancer

August 1st 2019

Walter M. Stadler, MD, Fred C. Buffett Professor of Medicine and Surgery, dean for clinical research, director of the Genitourinary Oncology Program, and deputy director of the Comprehensive Cancer Center, at the University of Chicago Medicine, discusses the use of active surveillance in prostate cancer.

Dr. Cowan on the Role of Venetoclax in Multiple Myeloma

August 1st 2019

Andrew J. Cowan, MD, an assistant professor of medicine at University of Washington and hematologist/oncologist at Seattle Cancer Care Alliance, discusses the role of venetoclax (Venclexta) in multiple myeloma.

Dr. Flaherty on the Rationale to Explore Triplet Therapy in BRAF V600E-Mutant Melanoma

August 1st 2019

Keith T. Flaherty, MD, director, Henri and Belinda Termeer Center for Targeted Therapy and director of clinical research, Massachusetts General Hospital Cancer Center, and professor of medicine, Harvard Medical School, discusses the rationale to explore triplet therapy in BRAF V600-mutant melanoma.

Dr. Rischin on KEYNOTE-048 Results in Head and Neck Squamous Cell Carcinoma

August 1st 2019

Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the phase III KEYNOTE-048 trial, which examines pembrolizumab or pembrolizumab plus chemotherapy versus EXTREME as first-line therapy for patients with recurrent/metastatic head and neck squamous cell carcinoma.

Dr. Nathan on 5-Year Survival Outcomes of COMBI-d and COMBI-v Trials in BRAF V600-Mutant Melanoma

August 1st 2019

Paul D. Nathan, MBBS, PhD, FRCP, discusses the 5-year analysis of the COMBI-d and COMBI-v trials, which look at the long-term effects of dabrafenib plus trametinib in patients with BRAF V600–mutant unresectable or metastatic melanoma.

Dr. Tan Discusses the FDA Approval of Darolutamide in M0CRPC

July 31st 2019

Winston Tan, MD, hematologist/oncologist, Mayo Clinic, discusses the FDA approval of darolutamide (Nubeqa) in nonmetastatic castration-resistant prostate cancer (M0CRPC).

Dr. Straus on the 3-Year Results of the ECHELON-1 Study in Hodgkin Lymphoma

July 31st 2019

David J. Straus, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the 3-year follow-up results of the ECHELON-1 study, which examines brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma.

Dr. Neelapu on Third-Line CAR T-Cell Therapy in Large B-Cell Lymphoma

July 31st 2019

Sattva Neelapu, MD, discusses the use of CAR T-cell therapy in the third-line setting for patients with large B-cell lymphoma.

Dr. Polsky on the Predictive Value of ctDNA in BRAF-Mutant Melanoma

July 30th 2019

David Polsky, MD, PhD, Alfred W. Kopf, MD Professor of Dermatologic Oncology, Ronald O. Perelman Department of Dermatology, professor, Department of Pathology, and director, Pigmented Lesion Service, NYU Langone’s Perlmutter Cancer Center, discusses the predictive value of circulating tumor DNA (ctDNA) in BRAF-mutant melanoma.

Dr. Sehgal on the Clinical Implications of CAR T-Cell Therapy in DLBCL

July 30th 2019

Alison R. Sehgal, MD, assistant professor of medicine, hematologist/medical oncologist, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, discusses the clinical implications of CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL).